BioSpace News Archive

ACG, a leading supplier of fully integrated solutions to the global pharmaceutical and nutraceutical industry, is delighted to announce its new ACGcaps™ NTone and ACGcaps™ TSafe range of capsules for the Nutraceutical market.

Ocean Biomedical, Inc. announces that it has confidentially submitted a draft Registration Statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock.

March 25, 2021 10:59 UTC Bristol Myers Squibb Announces RELATIVITY-047, a Trial Evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab) in Patients with Previously Untreated Metastatic or Unresectable Melanoma, Meets Primary Endpoint of Progression-Free Survival First Phase 3 data to be reported from a trial evaluating an anti-LAG-3 antibody Relatlimab is the company’s third distinct checkpoint inhibitor to demonstrate a benefit for patients PRINCETON

While there is much excitement about the arrival of the COVID-19 vaccine, there is also some skepticism with polls showing that up to 30 percent of Americans say they are not sure that they will get the vaccine.

Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its proprietary APOLLO Anterior Cervical Plate (ACP) system, featuring a sleek 1.9mm design, with Hyper-Angulation™ variability in the Cephalad-Caudal

Phase 2 study design based on successful Phase 1/2 trial including use of Tinnitus Functional Index (TFI) responder analysis for primary efficacy endpoint Patient enrollment criteria refined to enrich study population Top-line results expected in mid-2022

Prelude Corporation, a leader in molecular diagnostics and precision medicine for early stage breast cancer, announced that it has entered into an agreement with MultiPlan, Inc., the nation’s leading provider of healthcare cost management solutions to participate in MultiPlan’s primary and complementary networks.

Solugen Inc. and Nanotronics announced a partnership intended to ensure clean water production and safety.

Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for sleep apnea and related disorders, announced today that it has raised $25 million in a Series B financing led by existing investor, Morningside Ventures, and joined by new investors, Seligman Investments and Tao Capital Partners.

Patient enrollment and dosing in the Phase 1/2 clinical trial of BDTX-189 continue to track in line with projections at initiation of the study, with dose-escalation portion on track to complete in first half of 2021; initiation of safety expansion cohort anticipated in the second quarter of 2021 with start of Phase 2 portion planned for second half of 2021 BDTX-1535, a brain-penetrant MasterKey inhibitor of EGFR mutations for glioblastoma multiforme (GBM) and solid tumors